Reactive nitrogen species

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

Retrieved on: 
Tuesday, May 7, 2024
Research, Robotics, Oncology, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Risk, Innovation system, Doctor of Philosophy, SMC, RNS, Sheba Medical Center, Medicine, RMC, Oncology nursing, Purdue University, Canady, ROS, Surgical oncology, Entrepreneurship, Plasma, Johns Hopkins University, Patient, Multi, Argon, Safety, George Washington University, Microsoft Access, Cell death, Survival, IDE, University of Massachusetts, Treatment, Multimedia, Reactive nitrogen species, Engineer, CHCP, University, Apoptosis, FACS, Field line, Airline, Rush University Medical Center, Reactive oxygen species, Nursing

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

Key Points: 
  • US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
  • The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
  • The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
  • For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .

Groundbreaking Results Using Canady Helios™ Cold Plasma Treatment Published in MDPI Journal “Cancers”

Retrieved on: 
Wednesday, August 2, 2023
Research, Technology, Medical Devices, Surgery, Health Technology, Biotechnology, Robotics, Health, Science, Oncology, Canady, Cell death, RNS, Histone, Survival, Clinical trial, Immunotherapy, CHCP, Irreversible electroporation, Plasma, ROS, Cancer, LRR, Patient, Sheba Medical Center, Reactive oxygen species, Apoptosis, Education minister, Cell division, FACS, Neoplasm, Rush University Medical Center, Recurrence, FDA, Reactive nitrogen species, Messenger, Pharmaceutical industry

It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.

Key Points: 
  • It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
  • The recent trial reveals that treating the surgical margin following a tumorectomy significantly reduced local recurrence and increased overall survival.
  • CHCP opens a new and promising treatment for addressing the challenges of eradicating microscopic residual cancer cells following surgical tumor resection.
  • Jerome Canady, M.D., FACS, CEO stated, “We are very pleased to have our results published in the peer reviewed journal 'Cancers'.

JCRI-ABTS and USMI Reports Statistically Significant Results of the Canady Helios Cold Plasma Phase 1 Clinical Trial on Patients with Stage 4 and Recurrent Advanced Solid Tumors

Retrieved on: 
Thursday, June 15, 2023
Other Health, Research, General Health, Oncology, Medical Devices, Clinical Trials, Science, Surgery, Biotechnology, Alternative Medicine, FDA, Health, Anoxic waters, DNA, Radiation, IRE, Cell death, RNS, Safety, CAP, Survival, Cancer, Ovary, Breast, Global health, Reactive nitrogen species, Human embryonic stem cells clinical trials, Prostate, Treatment of lung cancer, Immunotherapy, CHCP, Messenger, Glioblastoma, ASCO, Irreversible electroporation, ROS, Sarcoma, SMC, Clinical trial, LRR, Patient, Risk, Melanoma, Sheba Medical Center, Plasma, Annual general meeting, Education minister, IDE, Rush University Medical Center, RUMC, Reactive oxygen species, Society, Medical imaging

(ClinicalTrials.gov identifier: NCT04267575)

Key Points: 
  • (ClinicalTrials.gov identifier: NCT04267575)
    Cancer remains a significant global health challenge, with over 1.9 million new cases and 608,570 cancer-related fatalities in the United States in 2021.
  • USMI’s Canady Helios Cold Plasma (CHCP) system, a non-thermal (26-30°C) and non-contact Cold Atmospheric Plasma (CAP) jet, offers a promising solution.
  • Twenty patients ranging from 26-85 years of age undergoing surgery for advanced stage 4 or recurrent solid tumors were enrolled.
  • Patients with preoperative treatments such as neoadjuvant chemotherapy, immunotherapy, radiation, and previous surgery were eligible.

Pancreatic Cancer Cells Harness Normal Tissue Turnover to Build Protective Barriers

Retrieved on: 
Monday, April 4, 2022
LaRue, Therapy, New York University Grossman School of Medicine, NYU Langone Health, Pancreatic cancer, Metabolism, NYU, Nutrient, SU2C, Malignancy, Biochemistry, GOT1, Growth, Arginine, Coronavirus Scientific Advisory Board (Turkey), KRAS, RNS, Lustgarten Foundation for Pancreatic Cancer Research, Pharmacology, Division, Doctor of Philosophy, Environment, Pancreatic tumor, Science, National Institutes of Health, National Academies of Sciences, Engineering, and Medicine, Neoplasm, Nitric oxide synthase 2 (inducible), Ultimate tensile strength, Cancer, National academy, Macrophage, Reactive nitrogen species, National, Radiation therapy, Autophagy, Kimmelman, Animal, Department, Enzyme, Protein, MRC1, Wound healing, Collagen, Medical imaging, Dietary supplement, Pharmaceutical industry

Past studies have shown that immune cells called macrophages contribute to a process called desmoplasia, which is caused by the abnormal turnover and excessive deposition of collagen that insulates pancreatic cancers.

Key Points: 
  • Past studies have shown that immune cells called macrophages contribute to a process called desmoplasia, which is caused by the abnormal turnover and excessive deposition of collagen that insulates pancreatic cancers.
  • This, in turn, caused neighboring, supportive stellate cells to build collagen-based meshes around tumors, say the study authors.
  • "Our results revealed how pancreatic tumors program macrophages to contribute to the construction of fibrotic barriers," says first study author Madeleine LaRue, PhD.
  • Pancreatic cancer remains difficult to treat in large part due to the extensive network of fibrotic tissue around tumors.

USMI and JCRI Research Teams Develop Treatment System for COVID and other Respiratory Infections and Diseases

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Medical Devices, Infectious Diseases, Health, Oncology, Patent, Â, Cancer, Photon, Continuous positive airway pressure, Serial block-face scanning electron microscopy, Medical Innovation Bill, Laparoscopy, Ozone, CHCP, Caps, Canady, Ion, Abdomen, Wound healing, HERO, Patient, ROS, Skin, Ministry of Education (Malaysia), USPTO, Endoscopy, Virus, United States Patent and Trademark Office, Lung cancer, Method, CEO, THE, Reactive nitrogen species, LLC, RNS, Plasma medicine, COVID-19, FOR, Research, Plasma, Hydroxyl radical, Breast cancer, Singlet oxygen, Vaccine, Medical imaging

17/284,762) entitled SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERIC PLASMA.

Key Points: 
  • 17/284,762) entitled SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERIC PLASMA.
  • Jerome Canady, MD (CEO of USMI) stated, This is a very important addition to the companys patent portfolio.
  • JCRI-ABTS is also conducting research using the HERO system to deliver CAPs to treat cancer and other diseases to the abdomen and other body cavities via cannulas, laparoscopes, and endoscopes.
  • JCRI-ABTS is using Canady Helios Cold Plasma to research and develop new methods to selectively treat and eradicate cancer.